# Bayer to acquire Perfuse Therapeutics

Bayer agreed to fully acquire Perfuse Therapeutics, a biopharmaceutical company developing PER-001 for glaucoma and diabetic retinopathy. The deal complements Bayer's ophthalmology pipeline.

- Type: Acquisition
- Announced: 2026-05-06
- Status: announced
- Products: PER-001 (endothelin receptor antagonist for glaucoma and diabetic retinopathy)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bayer](https://endata.com/companies/2148.md) (acquirer)
- [Perfuse Therapeutics](https://endata.com/companies/91754.md) (target)

## Sources

- [bayer.com](https://www.bayer.com/media/en-us/bayer-to-acquire-perfuse-therapeutics-to-complement-ophthalmology-pipeline/), 2026-05-06: "With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.